Learning Center
We keep you up to date on the latest tax changes and news in the industry.

How the OBBBA Reshapes R&D Tax Relief for Companies

The recent reform of Research and Experimental (R&D) tax provisions through the One Big Beautiful Bill Act (OBBBA) has fundamentally changed the strategic landscape for businesses engaged in innovation. By reinstating immediate deductions for domestic R&D expenditures, the legislation aims to bolster incentives for innovation and development-critical components of modern business success.

Signed into law on July 4, 2025, the OBBBA permanently reinstates the ability for businesses to deduct domestic R&D expenditures immediately. This crucial adjustment, now encapsulated in IRC Section 174A, reverses the controversial stipulations of the Tax Cuts and Jobs Act (TCJA) of 2017, which required capitalization and amortization of these costs.

Decoding R&D Expenditures - R&D costs, pivotal in product development and improvement, include many elements, such as:

  • Employee wages engaged in research projects.
  • Expenditures on materials and supplies used in research.
  • Contractual expenses for third-party research services.
  • Overhead costs related to R&D facilities and equipment.
Image 2

Historical Context of R&D Expensing - Prior to the TCJA’s amendments in 2022, businesses enjoyed the flexibility of either immediately expending R&D costs or amortizing them over a minimum of five years under former Section 174, offering a vital financial infusion for innovation-driven enterprises.

The TCJA drastically altered this framework, necessitating the capitalization and amortization of R&D expenses over five years domestically and 15 years for foreign research, thereby imposing severe financial constraints—especially on startups.

Revamping R&D Under OBBBA - For tax years starting post-2024, the OBBBA redefines domestic R&D expensing:

  • Domestic R&D Expenditures: Provides a 100% immediate deduction in the year incurred, substantially enhancing the business incentive to conduct research within U.S. borders.
  • Foreign R&D Expenditures: Maintains the existing requirement to amortize costs over 15 years, compelling multinational companies to reconsider their research locations.

Strategic Options for Accelerated Expensing - The OBBBA introduces options for taxpayers to manage previously capitalized R&D costs between 2022-2024:

  • Option 1: Full Expensing in 2025: Deduct the entire balance of remaining domestic R&D costs.
  • Option 2: Two-Year Amortization: Deduct unamortized balances over two years.
  • Option 3: Continue Amortization: Keep amortizing over the original schedule.
Image 1

Eligible small businesses have a unique avenue of retroactive expensing via amended returns, allowing them to reclaim taxes paid under more restrictive rules, provided they align with IRS guidelines under Rev Proc 2025-28.

Tax Code Interactions - The revamped R&D expensing rules must be considered in conjunction with other tax provisions like net operating loss, bonus depreciation, and business interest expense limitations. Aligning these elements can optimize tax strategies and lower tax liabilities.

Simplifying Accounting Changes - These changes are categorized as an automatic accounting method modification, simplifying compliance. Transitioning from prior capitalization mandates to claiming these deductions can offer a significant cash flow advantage.

Reach out to our office to analyze these strategic options and design a plan tailored to maximizing your tax benefits.

Image 3

Share this article...

Want tax & accounting tips and insights?

Sign up for our newsletter.

I confirm this is a service inquiry and not an advertising message or solicitation. By clicking “Submit”, I acknowledge and agree to the creation of an account and to the and .